Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7547366

Surfactant replacement therapy.

H L Halliday
View original source ↗Export metadata ↓

Abstract

Surfactant replacement therapy for treatment or prevention of the respiratory distress syndrome (RDS) has been studied intensively over the past decade. Randomized controlled trials have demonstrated a reduction in the odds of neonatal death of about 40% and of pulmonary air leaks of 35 to 70% depending upon the type of surfactant used. Prophylaxis or very early treatment is superior to later treatment, especially for the very preterm (< 28 week) infant. Natural (derived from animal lungs) surfactants have a more rapid onset of action than synthetic surfactants and may also provide better long-term benefits, but further comparative trials will be needed to demonstrate this conclusively. Surfactant treatment should not be viewed as a substitute for prenatal steroid therapy to enhance fetal lung maturity; the treatments are synergistic.

Explore related subjects

Clinical Trials as TopicHumansInfant, NewbornInjections, IntralesionalPulmonary SurfactantsRespiratory Distress Syndrome, NewbornSurvival RateTreatment OutcomeJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H L Halliday. 1995. Surfactant replacement therapy.. https://doi.org/10.1002/ppul.1950191147

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Consequences of event rate heterogeneity across non-randomized study sub-groups.

Analyses to compare non-randomized groups are more and more common in both post hoc analyses of randomized clinical trials data and in analyses of long-term observational data. In such cases, it is quite likely that there are unknown or uncollected sources of heterogeneity in event rates. Research has shown that an underlying source of heterogeneity in event rates which is not included in proportional hazards regression models leads to biased estimates for included covariate effect estimates and lower power to test them whether the source of heterogeneity is assumed to be fixed or random. We demonstrate here using several post hoc analyses of clinical trials data that a potentially common problem may be that the non-randomized groups which are to be compared have differential variability in their event rates. We then show through simulation that such underlying heterogeneity which varies across the groups, when ignored in the modelling, can lead to an attenuated regression effect estimate for comparing the two groups to each other, lower rejection rates for the effect, and Wald-based confidence intervals with potentially much lower coverage than nominal. When the groups are not significantly different, but heterogeneity differs between them, an analysis ignoring the heterogeneity can even result in a significant negative comparison.

Clinical Trials as Topic↗
PubMed2004

Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? A critical appraisal.

Cardiac resynchronization therapy (CRT) has been proposed as an alternative treatment in patients with severe, drug-refractory heart failure. The clinical results are promising, and improvement in symptoms, exercise capacity, and systolic left ventricular (LV) function have been demonstrated after CRT, accompanied by a reduction in hospitalization and a superior survival as compared with optimized medical therapy alone. However, 20% to 30% of patients do not respond to CRT. Currently, patients are selected mainly on electrocardiogram criteria (wide QRS complex, left bundle branch block configuration). In view of the 20% to 30% of nonresponders, additional selection criteria are needed. Echocardiography (and, in particular, tissue Doppler imaging) may allow further identification of potential responders to CRT, based on assessment of inter- and intraventricular dyssynchrony. In addition, echocardiography may allow optimal LV lead positioning and follow-up after CRT. In the current review, the different echocardiographic approaches to predict response to CRT are discussed. In addition, the use of echocardiography to guide LV lead positioning and follow-up after CRT are addressed.

Clinical Trials as Topic↗